Antimicrobials are commonly prescribed and contribute to the development of antimicrobial resistance in long-term care facilities (LTCFs). In 2010, the European Centre for Disease Prevention and Control initiated point prevalence surveys (PPS) of healthcare-associated infections and antimicrobial use in European LTCFs, performed by external contractors as the Healthcare-Associated infections in Long-Term care facilities (HALT) projects. Here, we investigated prevalence and characteristics of antimicrobial use and antimicrobial stewardship indicators in European LTCFs in 2016–17. Twenty-four European Union/European Economic Area (EU/EEA) countries, the former Yugoslav Republic of Macedonia and Serbia participated in the third PPS in European LTCFs. Overall, 4.9% (95% confidence interval: 4.8–5.1) of LTCF residents in the EU/ EEA participating countries received at least one antimicrobial. The most commonly reported Anatomical Therapeutic Chemical (ATC) groups were beta-lactam antibacterials/penicillins (J01C), other antibacterials (J01X) (e.g. glycopeptide antibacterials, polymyxins), quinolones (J01M), sulfonamides and trimethoprim (J01E), and other beta-lactams (J01D). Urinary tract infections and respiratory tract infections were the main indications for antimicrobial prescription. This PPS provides updated and detailed information on antimicrobial use in LTCFs across the EU/EEA that can be used to identify targets for future interventions, follow-up of these interventions and promote prudent use of antimicrobials in European LTCFs.

Antimicrobial use in european long-term care facilities: Results from the third point prevalence survey of healthcare-associated infections and antimicrobial use, 2016 to 2017

Zotti C. M.;Furmenti M. F.;
2018-01-01

Abstract

Antimicrobials are commonly prescribed and contribute to the development of antimicrobial resistance in long-term care facilities (LTCFs). In 2010, the European Centre for Disease Prevention and Control initiated point prevalence surveys (PPS) of healthcare-associated infections and antimicrobial use in European LTCFs, performed by external contractors as the Healthcare-Associated infections in Long-Term care facilities (HALT) projects. Here, we investigated prevalence and characteristics of antimicrobial use and antimicrobial stewardship indicators in European LTCFs in 2016–17. Twenty-four European Union/European Economic Area (EU/EEA) countries, the former Yugoslav Republic of Macedonia and Serbia participated in the third PPS in European LTCFs. Overall, 4.9% (95% confidence interval: 4.8–5.1) of LTCF residents in the EU/ EEA participating countries received at least one antimicrobial. The most commonly reported Anatomical Therapeutic Chemical (ATC) groups were beta-lactam antibacterials/penicillins (J01C), other antibacterials (J01X) (e.g. glycopeptide antibacterials, polymyxins), quinolones (J01M), sulfonamides and trimethoprim (J01E), and other beta-lactams (J01D). Urinary tract infections and respiratory tract infections were the main indications for antimicrobial prescription. This PPS provides updated and detailed information on antimicrobial use in LTCFs across the EU/EEA that can be used to identify targets for future interventions, follow-up of these interventions and promote prudent use of antimicrobials in European LTCFs.
23
46
1
12
https://www.eurosurveillance.org/deliver/fulltext/eurosurveillance/23/46/eurosurv-23-46-5.pdf?itemId=/content/10.2807/1560-7917.ES.2018.23.46.1800394&mimeType=pdf&containerItemId=content/eurosurveillance
AMR; HAI; LTCF; PPS; antimicrobial resistance; antimicrobial use; healthcare-associated infections; long-term care facility; point-prevalence survey; surveillance; Aged; Aged, 80 and over; Anti-Infective Agents; Cross Infection; Drug Utilization; Europe; Female; Health Care Surveys; Homes for the Aged; Humans; Long-Term Care; Male; Nursing Homes; Practice Patterns, Physicians'; Prevalence; Surveys and Questionnaires
Ricchizzi E.; Latour K.; Karki T.; Buttazzi R.; Jans B.; Moro M.L.; Nakitanda O.A.; Plachouras D.; Monnet D.L.; Suetens C.; Kinross P.; Lusignani L.S.; Strauss R.; Hedlova D.; Jindrak V.; Bosnjak Z.; Budimir A.; Gabriel E.; Jensen C.S.; Lyytikainen O.; Sarvikivi E.; Savey A.; Daniau C.; Schmidt N.; Ruscher C.; Adami M.-E.; Panagiotakis S.H.; Veress I.; Burns K.; Murphy H.; Zotti C.M.; Furmenti M.F.; Avelyte J.; Weydert M.; Basovska B.P.; Kochinski D.; Borg M.A.; Bonanno M.; Verhoef L.; Halonen K.; Eriksen H.-M.; Bentele H.; Wojkowska-Mach J.; Mazinska B.; Pacheco P.; Valente M.; Markovic-Denic L.; Krtinic G.; Garabasova M.K.; Stefkovicova M.; Caceres E.L.; Castillo M.J.T.; Soderblom T.; Hellman J.; Sartaj M.; Crockford T.; Cairns S.; Gibbons C.; Harrison W.; Jeffrey C.
File in questo prodotto:
File Dimensione Formato  
eurosurv-23-46-5.pdf

Accesso aperto

Tipo di file: PDF EDITORIALE
Dimensione 263.09 kB
Formato Adobe PDF
263.09 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1730775
Citazioni
  • ???jsp.display-item.citation.pmc??? 32
  • Scopus 53
  • ???jsp.display-item.citation.isi??? 23
social impact